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Abstract
Cellular heterogeneity is a hallmark of human neuro-
blastoma tumors and cell lines. Within a single neuro-
blastoma are cells from distinct neural crest lineages
whose relative abundance is significant for prognosis.
We postulate that a self-renewing multipotent tumor
stem cell, which gives rise to diverse cell lineages, is
the malignant progenitor of this cancer. To test this
hypothesis, we have established 22 cloned, pheno-
typically homogeneous populations of the three major
cell types from 17 neuroblastoma cell lines. In vitro,
malignant neuroblastoma stem cells, termed I-type
(intermediate type), have distinct morphologic, bio-
chemical, differentiative, and tumorigenic properties.
I-type cells express features of both neuroblastic (N)
cells (scant cytoplasm, neuritic processes, neurofila-
ments, pseudoganglia, and granin and neurotransmit-
ter enzyme expression) and substrate-adherent (S)
cells (extensive cytoplasm and vimentin and CD44
expression). Moreover, they show bidirectional differ-
entiation to either N or S cells when induced by specific
agents. I-type cells are significantly more malignant
than N- or S-type cells, with four- to five-fold greater
plating efficiencies in soft agar and six-fold higher
tumorigenicity in athymic mice. Differences in malig-
nant potential are unrelated to N-myc amplification/
overexpression or the ability to digest and migrate
through the extracellular matrix. Immunocytochemical
analyses of a small series of tumors reveal that fre-
quency of cells coexpressing N and S cell markers
correlates with poor prognosis. Thus, I-type stem cells
may be instrumental in the genesis and growth of
tumors in the patient. Their unique biology deserves
attention and further investigation.
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Introduction
Human neuroblastoma, the most commonly diagnosed
solid tumor in infants, is a cancer of the neural crest [1–3].
Within a single tumor, many of the cell phenotypes charac-
teristic of this transient embryonic structure, particularly
neuroblasts, non-neuronal (Schwann, perineurial, or satellite)
cells, and even melanocytes, may be present. It has been
shown that cellular heterogeneity and extent of maturation
(e.g., stroma-rich and stroma-poor tumors or high-risk and
low-risk tumors based on histologic grade) correlate with clin-
ical behavior, and these properties have been used for the
classification and prognosis of the disease [4].
This same cellular heterogeneity is manifest in cell lines
derived from these tumors. We and others have identified
three distinct cellular phenotypic variants frequently present in
human neuroblastoma cell lines [5,6]. Most common are sym-
pathoadrenal neuroblasts (N), which grow as poorly attached
aggregates of small, rounded cells with short neuritic process-
es. A second cell type resembles non-neuronal precursor cells,
as these large, flattened cells (termed S) attach strongly to
the substrate and show contact inhibition of cell growth. A third
cell type, termed I because its morphology is intermediate to
those of N and S, is a small, flattened, moderately adherent
cell, with or without neuritic processes, which forms aggregates
in culture. This cell type appears to represent a more primitive
stem cell, a progenitor of N- or S-type cells, capable both of self-
renewal and of bidirectional differentiation [7].
The three phenotypic variants present in most human
neuroblastoma cell lines display different tumorigenic poten-
tials [8,9]. S-type non-neuronal cells are nonmalignant: they
show no or very little anchorage-independent growth in soft
agar and do not form tumors in athymic mice. By contrast,
N-type cells form slowly growing tumors in 31% to 100%ofmice
and have higher plating efficiencies in soft agar than S cells.
Surprisingly, the two I-type cell lines previously examined,
BE(2)-C and SH-IN, had the highest tumor-forming capacities
and plating efficiencies of the three phenotypes. However, the
small number of I-type sublines precluded any generalizations
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about the relationship between the stem cell phenotype and
malignant potential.
Stem cells are defined as clonogenic cells capable of both
self-renewal and multilineage differentiation. Emerging evi-
dence from hematopoietic cancers has suggested that it is
the rare cancer stem cell that drives tumor formation and
growth [10]. Whereas some of the heterogeneity observed in
cancers arises from continuing mutagenesis and epigenetic
changes, some may also result from further differentiation
of cancer stem cells, with consequent changes in cancer
aggressiveness and malignancy. If neuroblastoma is a stem
cell cancer, the neuroblasts and stromal cells present in
human neuroblastoma tumors may represent divergent pop-
ulations derived from these tumor stem cells, and the relative
abundance of the three cell variants may influence their
clinical behavior. Recent studies of neuroblastoma tumors,
using cell sorting, short-term culture, and immunocytochem-
ical techniques, are consistent with this hypothesis. Stromal
cells were shown to contain identical genetic abnormalities
as tumor neuroblasts [11,12] and I-like cells have been
shown to be present in tumors [13]. It is clear that the role
played by malignant stem cells in neuroblastoma tumor
progression and relapse needs further investigation. Addi-
tional studies of homogeneous populations of I-like cell lines
are essential to understanding the cellular and molecular
biology of malignant neuroblastoma stem cells.
In the present study, we have extended our analysis of
human neuroblastoma I-type cells to five newly isolated
and two partially characterized cell lines [5,7]. We confirm
that I-type cells are malignant stem cells, capable of self-
renewal and proliferation as well as further differentiation.
More importantly, we show that these cells have the highest
malignant potential of the three neuroblastoma cell variants.
Finally, preliminary immunocytochemical studies to quan-
tify numbers of presumptive stem cells in tumor sections
have revealed a greater frequency of I-like cells in tumors of
patients whose disease progressed compared to those
with event-free survival. Further identification and character-
ization of this specific cell type may be pivotal in understand-
ing the basic and clinical biology of this enigmatic cancer.
Materials and Methods
Patients and Samples
Tumor and marrow specimens were obtained from
patients as part of their standard of care after informed
consent. Research using tumor samples was approved by
the Institutional Review Board of Memorial Sloan-Kettering
Cancer Center (New York, NY).
Cell Culture and Differentiation
Nine N-type cell lines and clones [SK-N-BE(1)n, BE(2)-
M17, LA1-55n, CHP-234, SMS-LHN, SMS-KAN, KCN-69n,
SH-SY5Y, and LA-N-6], four I-type cell lines [BE(2)-C, LA-N-
2, SH-IN, and CHP-212], and four S-type cell lines [LA1-5s,
SMS-KCNs, SK-N-BE(2)s, and SH-EP1] have been describ-
ed previously [5,8,14,15]. One N-type (SK-N-CH) and four
clonal I-type cell lines (SK-N-ER, SK-N-JD, SK-N-HM, and
SK-N-LP) were established from patients with recurrent
neuroblastoma. CB-JMN is a non–N-myc–amplified I-type
cell line isolated from a patient with a stage 3 tumor and was
a gift from Dr. C. Patrick Reynolds (Children’s Hospital, Los
Angeles, CA). Cells are cultured in a 1:1 mixture of Eagle’s
minimum essential medium (with nonessential amino acids)
and Ham’s nutrient mixture F12 supplemented with 10% fetal
bovine serum (HyClone, Logan, UT). In differentiation stud-
ies, I-type neuroblastoma cells were grown for 7 to 14 days in
the presence of 1 mM of all-trans retinoic acid (RA) or 10 mM
5-bromo-2V-deoxyuridine (BUdR) or forskolin (FSK), in con-
centrations determined in earlier experiments to yield optimal
differentiation [7,16].
Immunoblot Analysis
Cells in exponential growth phase were lysed by the
method of Ikegaki et al. [17] and proteins were separated
by standard techniques [18]. Blots were probed with anti-
bodies to chromogranin A (CgA; MAB319), neurofilament
protein 68 (NF68; MAB1615), heat shock protein 72/73
(MAB3516), vimentin (VIM; AB1620), and/or actin
(MAB1501R), all purchased from Chemicon International
(Temecula, CA). N-myc (sc-1452), which also recognizes
a-actinin4 (ACTN) [19], andCD44 (sc-7051) were fromSanta
Cruz Biotechnology, Inc. (Santa Cruz, CA). Tissue plasmino-
gen activator antibody was from ICN Pharmaceuticals
(Aurora, OH) whereas Hu antisera were a gift from Dr. M.
Rosenfeld (University of Pennsylvania, Philadelphia, PA).
Bound antibody was detected by chemiluminescence using
secondary antibodies conjugated to horseradish peroxidase.
The amount of protein was quantified by densitometry of
resulting Kodak XAR films and normalized to the amount
of actin or heat shock protein 72/73.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from cells in exponential growth
phase as previously described [18]. c-kit, CD133, and GAPD
expression was detected by a two-step semiquantitative
RT-PCR reaction using SuperScript II reverse transcriptase
according to the instructions of the manufacturer (Invitrogen,
Carlsbad, CA). Primers used for PCR were: c-kit (5V-CGAG-
TTGGCCCTAGACTTAGAA-3V and 5V-GGGGTGCCCAC-
TATCCTGGAGTT-3V), CD133 (5V-CCTGTTATGACAAGCC-
CATCACAA-3V and 5V-CGCAGGTTTCTCTATGAT-3V), and
GAPD (5V-GTGAAGGTCGGAGTCAACGGATTTGG-3V and
5V-ATGCCAGTGAGCTTCCCGTTCAGCT-3V). The thermal
cycler parameters were: 94jC for 5 minutes; 30 to 42 cycles
at 94jC for 30 seconds, 55jC to 57jC for 30 seconds,
and 72jC for 1 minutes; and a final extension at 72jC for
7 minutes. Ethidium bromide–stained PCR products were
resolved on 1% agarose gels and the amount of mRNA,
determined by scanning densitometry of resulting photo-
graphs, was normalized to that of GAPD.
Transformation and Tumorigenicity Assays
Procedures to determine anchorage-independent growth
in 0.33% Difco Bacto agar have been published [8]. BE(2)-C
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was included in all experiments as a positive control. Mean
colony-forming efficiency (CFE; the number of colonies with
>10 cells per cell inoculum  100) was determined in two to
four independent experiments. To determine tumorigenicity,
cells in the exponential growth phase were resuspended in
100 ml of medium with or without Matrigel (BD BioSciences,
Bedford, MA) and inoculated subcutaneously into female
BALB/c nu/nu athymic mice at 2  106 or 1  107 cells per
mouse, respectively. Mice were examined at twice-weekly
intervals and tumor volumes were estimated from measure-
ments in two dimensions.
Motility Invasion Assays
In vitro cell invasivity was measured by the method of
Albini et al. [20], using Matrigel Invasion Chambers (Becton
Dickinson, Bedford, MA), as previously described [21]. Cell
invasivity is expressed as the percentage of cells that
migrated through the coated membrane compared to un-
coated membrane.
Immunocytochemistry
Frozen sections from 15 archival tumors were fixed in 1:1
acetone/methanol at 20jC, permeabilized with 0.5% Triton
X-100, and immunostained sequentially with two primary
antibodies: S100A6 (calcyclin) and a mixture of neurofila-
ment 68 and 150. Bound antibody was detected chromogeni-
cally with biotinylated secondary antibody and the Vectastain
Elite ABC kit (Vector Laboratories, Burlingame, CA). Slides
of frozen N, S, and/or I cell cultures were included as controls
Figure 1. Phase contrast photomicrographs of human neuroblastoma cell
lines of the three different phenotypes, all at 135 magnification. (A) N-type
SK-N-CH; (B) S-type SH-EP1; and I-types (C) SK-N-JD, (D) SK-N-LP, (E)
SK-N-HM, and (F) SK-N-ER.
Figure 2. (A) Western blot analysis of N, I, and S cell lines stained for CgA,
CD44, and actin. Lane, line, phenotype: (1) BE(2)-M17, N; (2) SK-N-JD, I; (3)
SK-N-LP, I; (4) BE(2)-C, I; and (5) SH-EP1, S. (B) Bar graph showing relative
expression of three N marker proteins [neuronal-specific RNA-binding protein
Hu (Hu-IR), CgA, and neurofilament 68 (NF68)] and three S marker proteins
(CD44, VIM, and ACTN) in phenotypically homogeneous populations of two
N-type [BE(2)-M17 and SH- SY5Y], seven I-type [BE(2)-C, SH-IN, SK-N-HM,
SK-N-LP, SK-N-JD, SK-N-ER, and CB- JMN], and two S-type [LA1-5s and
SMS-KCNs] cell lines. Bar height represents the amount of protein (relative to
actin) as a percentage of maximum amount of protein present in any of the lines.
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for staining specificity. Results are expressed as percentage
of neurofilament-positive cells (N- and I-like cells) that also
express S100A6 (I-like cells). Statistical significance was
assessed using a one-tailed t-test.
Results
Morphologic Characterization of I-Type Cells
In the present study, we have compared six new human
neuroblastoma cell lines or clones (CB-JMN, SK-N-LP, SK-
N-JD, SK-N-ER, SK-N-CH, and SK-N-HM) with four cell
lines reported previously by us as I-type [BE(2)-C, LA-N-2,
CHP-212, and SH-IN] as well as N and S cell lines. Five
morphologic criteria were used to distinguish the three cell
line variants from each other: 1) degree of substrate attach-
ment; 2) nuclear/cytoplasmic ratio; 3) cell shape and polarity;
4) number and extent of neuritic processes; and 5) degree of
cell aggregation. As illustrated in Figure 1, C–F, I-type cell
lines typically display the following features that collectively
can be used to distinguish them from either N or S cells: 1)
they have small flattened cell bodies with prominent nuclei
and moderate amounts of cytoplasm, compared to N-type
cells with scant cytoplasm (Figure 1A) and flattened S cells
with abundant cytoplasm (Figure 1B); 2) unlike S cells, which
attach strongly to the underlying substrate and do not
mound, or N cells, which attach weakly and form pseudo-
ganglia, I cells adhere to both the substrate and each other,
forming mounding, contiguous layers of cells; 3) I-type cells
appear more radially symmetric, whereas N and S cells most
often show cellular polarity (i.e., one axis is greater than the
other); and 4) whereas N cells have numerous, small distinct
neuritic processes and S cells often have large flat lamelli-
podia, I-type cells may or may not have neuritic processes
that, when present, are short and few in number. Using these
criteria, one line (SK-N-CH) is N-type and the remaining five
lines are all I-like.
Biochemical Confirmation of I-Type Cells as Stem Cells
To assess the biochemical properties of the five I-like
cell lines and confirm their I-type cell phenotype [7], the
presence and amounts of six phenotype-specific marker
proteins were examined byWestern blot analysis. Numerous
neuronal-specific proteins found in N-type BE(2)-M17 and
SH-SY5Y cells, but not in S cells, include CgA, all three
neurofilament proteins (NF68, NF150, and NF200), and the
neuronal-specific RNA-binding protein Hu (Hu-IR) (Refs.
[5,6,8]; data not shown). Marker proteins distinguishing
S-type LA1-5s and SMS-KCNs cells from N cells include
CD44, a cell surface receptor protein involved in cell/matrix
interactions, the intermediate filament VIM, the actin-binding
protein ACTN, and the nuclear S100A6 (calcyclin) protein
(Refs. [5,6,19]; data not shown). We had previously shown
that homogeneous clones or populations of I cells express
both N and S marker proteins [7]. As illustrated in Figure 2A
and summarized in Figure 2B, all of the I-type cell lines and
clones express marker proteins of both N and S cell types.
Thus, the biochemical profiles of the five new cell lines are
consistent with their identification as I cells.
As further evidence that these I cells are stem cells, we
measured steady-state RNA levels for two proteins
expressed by stem cells, CD133 and c-kit (CD117), in our
series of phenotypic variants. Both cell surface antigens are
present in hematopoietic stem cells [22]. Moreover, CD133
is expressed on all fetal human neural stem cells [23,24],
whereas c-kit expression appears to be restricted to a
subpopulation of neural crest stem cells [25]. As shown in
Figure 3, although N and S cell variants show little or no
expression, I-type cells have abundant mRNA for both
proteins.
Differentiation Induction
A distinctive feature of I-type neuroblastoma stem cells is
their ability to differentiate bidirectionally into N and S cell
types. Our previous studies of BE(2)-C and SH-IN showed
that, in response to differentiation-inducing agents (e.g.,
FSK, RA, or BUdR), the majority of cells either converts to a
neuroblastic phenotype or becomesS-like [7]. The new I-type
cell lines were tested for their ability to show bidirectional
Figure 3. RT-PCR analysis of relative expression levels ± SEM of CD133
and c-kit in three N-type (n), five I-type ( ), and two S-type (5) human
neuroblastoma cell lines. Each bar represents the average of one to five
separate determinations. Lane, line: (1) KCN-69n; (2) LA1-55n; (3) BE(2)-
M17; (4) BE(2)-C; (5) SK-N-LP; (6) LAN-2; (7) CB-JMN; (8) SK-N-ER; (9)
SH-EP1, and (10) LA1-5s.
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differentiation. As illustrated in part in Figure 4, treatment with
RA induced a neuroblastic phenotype (formation of pseudo-
ganglia and neurites), whereas BUdR induced an S cell
phenotype (cell flattening and contact inhibition) in the five
new I-type cell lines and LA-N-2, as well as in BE(2)-C. In two
other lines (SH-IN and CHP-212), RA and BUdR both cause
S-type cell differentiation, whereas FSK induces a neuro-
blastic phenotype. Morphologic changes were confirmed
immunochemically by analysis of the N cell marker proteins,
Hu and CgA, and the S cell marker, VIM (data not shown).
Thus, I cells represent a unique cell phenotype characterized
by a distinct morphology, biochemistry, and differentiation
potential.
N-myc Protein Expression
N-myc expression has previously been shown to correlate
with the expression of a neuroblastic phenotype in human
neuroblastoma cells [8,26,27]; S-type cells express little or
no oncoprotein [8]. Therefore, we determined levels of N-myc
protein in N and I cell variants from both N-myc–amplified
and nonamplified cell lines (Table 1). Whereas mean N-myc
protein levels are 64-fold higher in N-myc–amplified lines
compared to nonamplified lines, they do not differ significantly
between N- and I-type cells within either group.
Anchorage-Independent Growth Potential and Tumorigenicity
of I-Type Stem Cells
Our previous studies of 21 different human neuroblasto-
ma cell lines or clonal variants showed that cell phenotype
has a dramatic influence on malignant potential [8]. Although
N-type cells are tumorigenic, forming colonies in soft agar
and/or tumors in athymic mice, S-type cells, even at very
high inocula, do not form colonies or tumors. Interestingly,
two clonal stem cell lines, BE(2)-C and SH-IN, appeared
more malignant than either their N or their S cell counter-
parts. Therefore, to determine whether the cancer stem cell
is inherently more malignant than N- or S-type cells, we
compared CFE in soft agar for six I-type, four N-type, and
three S-type clones. As shown in Figure 5, CFEs of S-type
lines range from 0.01% to 1.6%, whereas those of the N-type
lines range from 2.9% to 7.4%. By contrast, I-type lines have
CFEs that range from 18.9% to 57.6%, significantly (four- to
five-fold) greater than N-type cells (P < .001). It is clear that
phenotype, not level of N-myc protein, determines malignant
potential. For example, I-type cell lines CB-JMN and SK-N-
ER (Figure 5, lanes 6 and 7 ), which do not amplify the
oncogene and express low levels of the oncoprotein, have
five- to six-fold higher plating efficiencies than N-types
BE(2)-M17 and SMS-KAN (lanes 1 and 2), which amplify
Figure 4. Effects of 1 M RA and 10 M BUdR on the cell phenotype of: (1) BE(2)-C; (2) SK-N-ER; and (3) SK-N-HM I-type cells. Note that whereas RA induces a
neuroblastic (N) phenotype, BUdR induces an S cell phenotype.
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the N-myc gene 130- to 150-fold, respectively [8,14] and
contain high levels of the oncoprotein.
As a second method to determine the malignant potential
of human neuroblastoma phenotypic variants, we injected
cells from seven I-type cell lines [BE(2)-C, SK-N-HM, CB-
JMN, SH-IN, SK-N-ER, SK-N-JD, and SK-N-LP] and five N-
type cell line [BE(2)-M17, SK-N-BE(1)n, LA1-55n, SK-N-CH,
and SH-SY5Y) into athymic mice and determined their
relative tumorigenicity (i.e., the ability to form tumors attain-
ing a volume of >300 mm3 in 1 month). Experiments done
using inocula of 107 cells suspended in medium or 2  106
cells in Matrigel yielded the same results. Compared to the
N-type lines, which formed tumors in only 12% of the 26
mice injected, I-type cells grew rapidly and formed tumors in
nearly 78% of 59 mice injected (Table 2). Moreover, as seen
in Table 2, tumorigenicity is correlated with cell phenotype,
not N-myc status. Thus, another distinctive feature of neu-
roblastoma stem cells is their enhanced malignant potential.
Cellular Invasivity and ECM Digestion
Because neural crest stem cells are highly migratory,
cell phenotype might influence metastasis. Thus, we as-
sessed the ability of phenotypic variants to digest and
migrate through the extracellular matrix (ECM) in Matrigel
invasion assays [20]. There are no phenotype-specific differ-
ences in these properties; approximately 75% of cells with
each phenotype digested and migrated through the ECM.
Table 1. Cell Phenotype, N-myc Amplification Status, and N-myc Protein
Levels in 15 Human Neuroblastoma Cell Lines.
Cell Line/Clone Phenotype* NMAy Amount of N-myc
Proteinz Mean ± SEM (n)
SK-N-BE(1)n N + 128.7 ± 17.6
BE(2)-M17 N + 149.6 ± 13.6
LA1-55n N + 155.9 ± 6.2 134.9 ± 9.0(5)
CHP-234 N + 108.4 ± 15.5
SMS-KAN N + 132.1 ± 11.6
LA-N-2 I + 111.7 ± 12.4
SK-N-LP I + 121.9 ± 10.5
SK-N-JD I + 78.4 ± 13.8 111.0 ± 9.8(5)ns
SK-N-HM I + 106.0 ± 12.5
CHP-212 I + 137.2 ± 13.5
SMS-LHN N – 1.0 ± 0.5
SH-SY5Y N – 2.1 ± 0.7 1.4 ± 0.4(3)
LA-N-6 N – 0.9 ± 0.6
CB-JMN I – 3.0 ± 1.1 2.4 ± 0.6(2)ns
SK-N-ER I – 1.6 ± 0.8
*N, neuroblastic; I, stem cell.
yNMA, N-myc amplification status: (+) amplified; () nonamplified.
zAmount of N-myc protein, relative to actin, expressed asmean ± SEMof three
to five separate cultures. ns, not significantly different from N-type group.
Table 2. Tumorigenicity in Athymic Mice of N and I Cell Lines.


















Total 46/59 77.9 ± 0.1%§
*NMA, N-myc amplification status: (+) amplified; () nonamplified.
yNumber of mice with tumor volumes of >300 mm3 after 1 month/number of
mice injected.
zPercentage ± SEM of mice with tumors.
§P < 0.001 compared to N-type cells.
Figure 5. Colony-forming efficiencies ± SEM in soft agar for four N-type (n),
six I-type ( ), and three S-type (5) cell lines. Lane, line: (1) BE(2)-M17; (2)
SMS-KAN; (3) KCN-69n; (4) SH-SY5Y; (5) BE(2)-C; (6) CB-JMN; (7) SK-N-
ER; (8) SK-N-JD; (9) SK-N-LP; (10) SH-IN; (11) SK-N-BE(2)s; (12) LA1-5s;
and (13) SH-EP1.
Figure 6. Frequency ± SEM of I-like cells in human neuroblastoma tumor
sections of patients who were progression-free (PF) (n = 10) or who relapsed
with disease (R) (n = 5). **P < .001.
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Likewise, levels of tissue plasminogen activator, a metal-
loprotease involved in ECM digestion, do not differ among
the three phenotypes (data not shown).
Double-Label Immunocytochemistry of Neuroblastoma
Tumors
Because malignant stem cells are present in many neu-
roblastoma cell lines and are the most malignant cell type,
we hypothesized that similar cells should be present in
tumors, especially in those with the worst prognosis. Thus,
as a preliminary study, we analyzed 15 tumors by immuno-
cytochemistry to determine whether: 1) I-like cells can be
detected in human neuroblastoma tumors, and 2) their
frequency correlates with disease progression. Frozen sec-
tions from 10 tumors from patients who were progression-
free and five from patients in which the tumor relapsed
were immunostained sequentially with antibodies specific
to S- and N-type cell antigens localized to different cellular
compartments. For example, in phenotypically homoge-
neous cell cultures, the S cell marker protein, S100A6
(calcyclin), localizes to nuclei of S and I cells, but not N cells,
whereas the N cell marker (neurofilaments) is abundant in
the cytoplasm only of neuronally differentiated N and I cells
(data not shown). In tumors, neuroblasts stain for neurofila-
ments only, stromal (and endothelial) cells for S100A6 only,
and I-like cells for both proteins. I-like cell frequency [the
number of doubly labeled cells (I) expressed as a percentage
of all tumor cells that express neurofilament proteins (Nand I)]
was determined microscopically. Putative cancer stem cells
could be detected in all tumors and in all stages, with
frequencies ranging from <1% (i.e., almost all tumor cells
were neuroblastic) up to 90% (i.e., most tumor cells appear
to have a stem cell phenotype). Most interesting—although
this is a preliminary study, with only a small number of
tumors—, there is a strong correlation between recurrence
and I-like cell frequency. As shown in Figure 6, the frequency
of I cells in tumors of patients who relapsed (52.2 ± 10.8%)
was 4.7-fold higher than that in tumors of patients who were
progression-free (11.2 ± 2.9%) (P > .001). These data
suggest that in the patient, as well as in the cell culture
model, cancer stem cells may play a significant role in the
genesis and/or relapse of neuroblastoma.
Discussion
Our previous studies of human neuroblastoma have focused
on the cellular heterogeneity present in cell lines in an
attempt to better understand the nature of this cancer and
to develop methods for its more effective treatment. Toward
this goal, we have identified and characterized three different
cell types commonly present in many primary human neu-
roblastoma cell lines: a neuroblastic (N-type) cell that resem-
bles a sympathoadrenal precursor cell, a substrate-adherent
(S-type) non-neuronal cell representing the glial/melanoblas-
tic precursor cell, and an intermediate (I-type) stem cell from
which the first two may arise [5–7]. More recently, these
same three cell types have been demonstrated to occur in
human neuroblastoma tumors as well: 1) Valent et al. [11]
isolated both N- and S-type cells from bonemarrow aspirates
grown in short-term culture; 2) using laser capture microdis-
section, Mora et al. [12] showed that the stromal component
of stage 4 tumors shares a common origin with the neuro-
blastic component; and 3) we have detected I-like cells in all
human neuroblastoma tumors by immunocytochemistry.
Thus, these human neuroblastoma cell line variants are not
in vitro cultural artifacts, but are most likely representative of
the heterogeneous in vivo cell types comprising this tumor.
Our studies of malignant potential in human neuroblasto-
ma cell lines [8] had suggested that I-type cells might be the
most tumorigenic of the three cell types commonly present
in cell lines. The present study confirms and extends those
findings to show that neuroblastoma stem cells as a group
are the most transformed, with higher colony-forming capac-
ities and greater growth potentials in athymic mice than
either N-type or S-type cells. Moreover, we show that it is
the malignant stem cell phenotype, not N-myc amplification
status or level of expression, which defines the malignant
potential of the neuroblastoma cell variants.
These cell culture results may have important implications
for understanding the genesis and response of tumors in
the patient. The intriguing, but preliminary, finding from our
immunocytochemical studies of 15 tumors, that the relative
abundance of putative stem cells correlates with poor prog-
nosis, suggests that neuroblastoma is indeed a stem cell
cancer. Analyses of additional tumors are currently under-
way. Further elucidation of the properties of malignant neu-
roblastoma stem cells both in vitro and in vivomay be crucial
for development of effective therapies for neuroblastoma.
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